RESUMEN
Diabetes has a significant global prevalence. Chronic hyperglycemia affects multiple organs and tissues, including bones. A large number of diabetic patients develop osteoporosis; however, the precise relationship between diabetes and osteoporosis remains incompletely elucidated. The activation of the AGE-RAGE signaling pathway hinders the differentiation of osteoblasts and weakens the process of bone formation due to the presence of advanced glycation end products. High glucose environment can induce ferroptosis of osteoblasts and then develop osteoporosis. Hyperglycemia also suppresses the secretion of sex hormones, and the reduction of testosterone is difficult to effectively maintain bone mineral density. As diabetes therapy, thiazolidinediones control blood glucose by activating PPAR-γ. Activated PPAR-γ can promote osteoclast differentiation and regulate osteoblast function, triggering osteoporosis. The effects of metformin and insulin on bone are currently controversial. Currently, there are no appropriate tools available for assessing the risk of fractures in diabetic patients, despite the fact that the occurrence of osteoporotic fractures is considerably greater in diabetic individuals compared to those without diabetes. Further improving the inclusion criteria of FRAX risk factors and clarifying the early occurrence of osteoporosis sites unique to diabetic patients may be an effective way to diagnose and treat diabetic osteoporosis and reduce the risk of fracture occurrence.
Asunto(s)
Osteoporosis , Humanos , Osteoporosis/metabolismo , Factores de Riesgo , Fracturas Osteoporóticas/metabolismo , Fracturas Óseas/metabolismo , Redes y Vías Metabólicas , Diabetes Mellitus/metabolismo , Densidad Ósea , Osteoblastos/metabolismo , Transducción de SeñalRESUMEN
Increased fracture risk in type 1 diabetes (T1D) patients is not fully captured by bone mineral density (BMD) by DXA. Advanced glycation end-products (AGEs) have been implicated in the increased fracture risk in T1D, yet recent publications question this. To test the hypothesis that enzymatic collagen cross-links rather than AGEs correlate with fracture incidence in T1D, we analyzed iliac crest biopsies from sex-matched, fracturing T1D patients (N = 5; T1DFx), 6 non-fracturing T1D patients (T1DNoFx), and 6 healthy subjects, by Raman microspectroscopy as a function of tissue age (based on double fluorescent labels), in intracortical and trabecular bone, to determine pyridinoline (Pyd), ε-N-Carboxymethyl-L-lysine, and pentosidine (PEN)). There were no differences in the clinical characteristics between the T1DFx and T1DNoFx groups. At trabecular forming surfaces, T1DFx patients had higher PEN and Pyd content compared to T1DNoFx ones. Previous studies have shown that elevated PEN does not necessarily correlate with fracture incidence in postmenopausal, long-term T1D patients. On the other hand, the elevated Pyd content in the T1DFx patients would be consistent with published studies showing a significant correlation between elevated trivalent enzymatic collagen cross-links and fracture occurrence independent of BMD. Collagen fibers with high Pyd content are more brittle. Thus, a plausible suggestion is that it is the enzymatic collagen cross-links that either by themselves or in combination with the adverse effects of increased AGE accumulation that result in fragility fracture in T1D.
Asunto(s)
Densidad Ósea , Colágeno , Diabetes Mellitus Tipo 1 , Fracturas Óseas , Productos Finales de Glicación Avanzada , Humanos , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Femenino , Colágeno/metabolismo , Adulto , Fracturas Óseas/metabolismo , Masculino , Productos Finales de Glicación Avanzada/metabolismo , Densidad Ósea/fisiología , Persona de Mediana Edad , Lisina/análogos & derivados , Lisina/metabolismo , Aminoácidos , Arginina/análogos & derivadosRESUMEN
The first evidence of the existence of vitamin A was the observation 1881 that a substance present in small amounts in milk was necessary for normal development and life. It was not until more than 100 years later that it was understood that vitamin A acts as a hormone through nuclear receptors. Unlike classical hormones, vitamin A cannot be synthesized by the body but needs to be supplied by the food as retinyl esters in animal products and ß-carotene in vegetables and fruits. Globally, vitamin A deficiency is a huge health problem, but in the industrialized world excess of vitamin A has been suggested to be a risk factor for secondary osteoporosis and enhanced susceptibility to fractures. Preclinical studies unequivocally have shown that increased amounts of vitamin A cause decreased cortical bone mass and weaker bones due to enhanced periosteal bone resorption. Initial clinical studies demonstrated a negative association between intake of vitamin A, as well as serum levels of vitamin A, and bone mass and fracture susceptibility. In some studies, these observations have been confirmed, but in other studies no such associations have been observed. One meta-analysis found that both low and high serum levels of vitamin A were associated with increased relative risk of hip fractures. Another meta-analysis also found that low levels of serum vitamin A increased the risk for hip fracture but could not find any association with high serum levels of vitamin A and hip fracture. It is apparent that more clinical studies, including large numbers of incident fractures, are needed to determine which levels of vitamin A that are harmful or beneficial for bone mass and fracture. It is the aim of the present review to describe how vitamin A was discovered and how vitamin A is absorbed, metabolized and is acting as a ligand for nuclear receptors. The effects by vitamin A in preclinical studies are summarized and the clinical investigations studying the effect by vitamin A on bone mass and fracture susceptibility are discussed in detail.
Asunto(s)
Densidad Ósea , Fracturas Óseas , Vitamina A , Humanos , Vitamina A/metabolismo , Vitamina A/sangre , Animales , Fracturas Óseas/metabolismo , Fracturas Óseas/etiología , Fracturas Óseas/epidemiología , Transducción de Señal , Osteoporosis/metabolismo , Deficiencia de Vitamina A/metabolismo , Deficiencia de Vitamina A/complicaciones , Huesos/metabolismoRESUMEN
PURPOSE OF REVIEW: The repair of bone after injury requires the participation of many different immune cell populations, which are derived from the hematopoietic lineage. The field of osteoimmunology, or the study of the interactions between bone and the immune system, is a growing field with emerging impact on both the basic science and clinical aspects of fracture healing. RECENT FINDINGS: Despite previous focus on the innate immune system in fracture healing, recent studies have revealed an important role for the adaptive immune system in bone repair. The composition of adaptive and innate immune cell populations present at the fracture site is significantly altered during aging and diet-induced obesity, which may contribute to delayed healing. Recent data also suggest a complicated relationship between fracture repair and systemic inflammation, raising the possibility that immune populations from distant sites such as the gut can impact the bone repair process. SUMMARY: These findings have important implications for the treatment of fracture patients with antibiotics or anti-inflammatory drugs. Furthermore, the effects of systemic inflammation on fracture repair in the contexts of aging or obesity should be carefully interpreted, as they may not be uniformly detrimental.
Asunto(s)
Curación de Fractura , Hematopoyesis , Humanos , Animales , Inflamación/metabolismo , Inflamación/patología , Huesos/metabolismo , Huesos/patología , Fracturas Óseas/terapia , Fracturas Óseas/metabolismo , Fracturas Óseas/patología , Obesidad/metabolismo , Obesidad/patologíaRESUMEN
Skeletal fragility is an increasingly recognised, but poorly understood, complication of both type 1 and type 2 diabetes. Fracture risk varies according to skeletal site and diabetes-related characteristics. Post-fracture outcomes, including mortality risk, are worse in those with diabetes, placing these people at significant risk. Each fracture therefore represents a sentinel event that warrants targeted management. However, diabetes is a very heterogeneous condition with complex interactions between multiple co-existing, and highly correlated, factors that preclude a clear assessment of the independent clinical markers and pathophysiological drivers for diabetic osteopathy. Additionally, fracture risk calculators and routinely used clinical bone measurements generally underestimate fracture risk in people with diabetes. In the absence of dedicated prospective studies including detailed bone and metabolic characteristics, optimal management centres around selecting treatments that minimise skeletal and metabolic harm. This review summarises the clinical landscape of diabetic osteopathy and outlines the interplay between metabolic and skeletal health. The underlying pathophysiology of skeletal fragility in diabetes and a rationale for considering a diabetes-based paradigm in assessing and managing diabetic bone disease will be discussed.
Asunto(s)
Huesos , Diabetes Mellitus Tipo 2 , Fracturas Óseas , Humanos , Huesos/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/complicaciones , Fracturas Óseas/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/fisiopatología , Glucemia/metabolismo , Densidad Ósea/fisiologíaRESUMEN
The present study simulates the fracture behavior of diabetic cortical bone with high levels of advanced glycation end-products (AGEs) under dynamic loading. We consider that the increased AGEs in diabetic cortical bone degrade the materials heterogeneity of cortical bone through a reduction in critical energy release rates of the microstructural features. To simulate the initiation and propagation of cracks, we implement a phase field fracture framework on 2D models of human tibia cortical microstructure. The simulations show that the mismatch between the fracture properties (e.g., critical energy release rate) of osteons and interstitial tissue due to high AGEs contents can change crack growth trajectories. The results show crack branching in the cortical microstructure under dynamic loading is affected by the mismatches related to AGEs. In addition, we observe cortical features such as osteons and cement lines can prevent multiple cracking under dynamic loading even with changing the mismatches due to high AGEs. Furthermore, under dynamic loading, some toughening mechanisms can be activated and deactivated with different AGEs contents. In conclusion, the current findings present that the combination of the loading type and materials heterogeneity of microstructural features can change the fracture response of diabetic cortical bone and its fragility.
Asunto(s)
Hueso Cortical , Productos Finales de Glicación Avanzada , Soporte de Peso , Humanos , Hueso Cortical/metabolismo , Productos Finales de Glicación Avanzada/metabolismo , Fenómenos Biomecánicos , Fracturas Óseas/metabolismo , Tibia/metabolismo , Análisis de Elementos Finitos , Estrés MecánicoRESUMEN
Adrenal adenomas/incidentalomas with mild autonomous cortisol secretion (MACS)/subclinical hypercortisolism (SH) are often associated with metabolic syndrome, glucocorticoid-induced osteoporosis, and fractures. In this background, the present systematic review and meta-analysis aimed to collate the available evidence and provide a summary of the effect of MACS/SH on bone health in terms of fractures, osteoporosis/osteopenia, microarchitecture, and bone turnover. PubMed/MEDLINE, Embase, and Web of Science databases were systematically searched for observational studies reporting prevalence of fractures, osteoporosis/osteopenia or data on bone microarchitecture/bone turnover markers (BTMs). Following literature search, 16 observational studies were included. Pooled prevalence of any fractures (vertebral and non-vertebral), vertebral fractures, and osteoporosis/osteopenia in MACS/SH were 43% [95% confidence intervals (CI): 23%, 62%], 45% (95% CI: 22%, 68%) and 50% (95% CI: 33%, 66%), respectively. On meta-regression, age, sex, 24-hour urinary free cortisol, and dehydroepiandrosterone-sulfate did not predict fracture risk. The likelihood of any fractures [odds ratio (OR) 1.61; 95% CI: 1.18, 2.20; P = 0.0026], vertebral fractures (OR 2.10; 95% CI: 1.28, 3.45; P = 0.0035), and osteoporosis/osteopenia (OR 1.46; 95% CI: 1.15, 1.85; P = 0.0018) was significantly higher in adrenal adenomas and MACS/SH than non-functional adrenal adenomas. Subjects with MACS/SH had significantly lower bone mineral density (BMD) at lumbar spine [mean difference (MD) -0.07 g/cm2; 95% CI: -0.11, -0.03; P = 0.0004) and femoral neck (MD -0.05 g/cm2; 95% CI: -0.08, -0.02; P = 0.0045) than their non-functional counterparts. Limited data showed no significant difference in BTMs. Publication bias was observed in the pooled prevalence of any fractures, vertebral fractures and pooled MD of femoral neck BMD. To conclude, people with adrenal adenomas/incidentalomas and MACS/SH are at a 1.5- to 2-fold higher likelihood of fractures and osteoporosis/osteopenia compared to non-functional adrenal adenomas and should routinely be screened for bone disease. Nevertheless, considering the modest sample size of studies and evidence of publication bias, larger and high-quality studies are required (CRD42023471045).
Mild autonomous cortisol secretion (MACS), often also referred to as subclinical hypercortisolism (SH), is usually associated with an underlying adrenal incidentaloma (AI), an adrenal mass incidentally found during abdomen imaging. Although signs of overt cortisol excess are lacking, subjects with MACS/SH often have features of metabolic syndrome, osteoporosis and fractures. The present systematic review and meta-analysis showed that the pooled prevalence of any fractures (vertebral and nonvertebral), vertebral fractures, and osteoporosis/osteopenia in MACS/SH were 43%, 45%, and 50%, respectively. People with adrenal adenomas/incidentalomas and MACS/SH are at a 1.5- to 2-fold higher likelihood of fractures and osteoporosis/osteopenia compared to nonfunctional adrenal adenomas. Besides, subjects with MACS/SH had significantly lower bone mineral density at lumbar spine and femoral neck than their nonfunctional counterparts. It is thus imperative to assess bone health in all subjects with MACS/SH.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Síndrome de Cushing , Fracturas Óseas , Hidrocortisona , Humanos , Hidrocortisona/metabolismo , Síndrome de Cushing/complicaciones , Síndrome de Cushing/metabolismo , Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasias de las Glándulas Suprarrenales/metabolismo , Fracturas Óseas/epidemiología , Fracturas Óseas/metabolismo , Factores de Riesgo , Huesos/metabolismo , Huesos/patología , Adenoma/metabolismo , Adenoma/complicaciones , Adenoma/epidemiologíaRESUMEN
BACKGROUND: Fractures heal through a process that involves angiogenesis and osteogenesis but may also lead to non-union or delayed healing. Bone marrow mesenchymal stem cells (BMSCs) have been reported to play a pivotal role in bone formation and vascular regeneration and the p75 neurotrophin receptor (p75NTR) as being an important regulator of osteogenesis. Herein, we aim to determine the potential mediation of BMSCs by p75NTR in bone healing. METHODS: Rat BMSCs were identified by flow cytometry (FCM) to detect cell cycle and surface markers. Then transfection of si/oe-p75NTR was performed in BMSCs, followed by Alizarin red staining to detect osteogenic differentiation of cells, immunofluorescence double staining was performed to detect the expression of p75NTR and sortilin, co-immunoprecipitation (CO-IP) was conducted to analyze the interaction between p75NTR and sortilin, and EdU staining and cell scratch assay to assess the proliferation and migration of human umbilical vein endothelial cells (HUVECs). The expression of HIF-1α, VEGF, and apoptosis-related proteins were also detected. In addition, a rat fracture healing model was constructed, and BMSCs-si-p75NTR were injected, following which the fracture condition was observed using micro-CT imaging, and the expression of platelet/endothelial cell adhesion molecule-1 (CD31) was assessed. RESULTS: The results showed that BMSCs were successfully isolated, p75NTR inhibited apoptosis and the osteogenic differentiation of BMSCs, while si-p75NTR led to a decrease in sortilin expression in BMSCs, increased proliferation and migration in HUVECs, and upregulation of HIF-1α and VEGF expression. In addition, an interaction was observed between p75NTR and sortilin. The knockdown of p75NTR was found to reduce the severity of fracture in rats and increase the expression of CD31 and osteogenesis-related proteins. CONCLUSION: Silencing p75NTR effectively modulates BMSCs to promote osteogenic differentiation and angiogenesis, offering a novel perspective for improving fracture healing.
Asunto(s)
Fracturas Óseas , Células Madre Mesenquimatosas , Animales , Humanos , Ratas , Angiogénesis , Células de la Médula Ósea , Diferenciación Celular/genética , Células Cultivadas , Células Endoteliales , Fracturas Óseas/metabolismo , Células Madre Mesenquimatosas/metabolismo , Osteogénesis/genética , Receptor de Factor de Crecimiento Nervioso/metabolismo , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/metabolismoRESUMEN
Bone is regarded as one of few tissues that heals without fibrous scar. The outer layer of the periosteum is covered with fibrous tissue, whose function in bone formation is unknown. We herein developed a system to distinguish the fate of fibrous-layer periosteal cells (FL-PCs) from the skeletal stem/progenitor cells (SSPCs) in the cambium-layer periosteum and bone marrow in mice. We showed that FL-PCs did not participate in steady-state osteogenesis, but formed the main body of fibrocartilaginous callus during fracture healing. Moreover, FL-PCs invaded the cambium-layer periosteum and bone marrow after fracture, forming neo-SSPCs that continued to maintain the healed bones throughout adulthood. The FL-PC-derived neo-SSPCs expressed lower levels of osteogenic signature genes and displayed lower osteogenic differentiation activity than the preexisting SSPCs. Consistent with this, healed bones were thinner and formed more slowly than normal bones. Thus, the fibrous periosteum becomes the cellular origin of bones after fracture and alters bone properties permanently.
Asunto(s)
Diferenciación Celular , Curación de Fractura , Fracturas Óseas , Osteogénesis , Periostio , Animales , Periostio/metabolismo , Ratones , Osteogénesis/fisiología , Curación de Fractura/fisiología , Fracturas Óseas/patología , Fracturas Óseas/metabolismo , Células Madre/metabolismo , Células Madre/citología , Ratones Endogámicos C57BL , Callo Óseo/metabolismo , Callo Óseo/patología , MasculinoRESUMEN
The term "fracture" pertains to the occurrence of bones being either fully or partially disrupted as a result of external forces. Prolonged fracture healing can present a notable danger to the patient's general health and overall quality of life. The significance of osteoblasts in the process of new bone formation is widely recognized, and optimizing their function could be a desirable strategy. Therefore, the mending of bone fractures is intricately linked to the processes of osteogenic differentiation and mineralization. MicroRNAs (miRNAs) are RNA molecules that do not encode for proteins, but rather modulate the functioning of physiological processes by directly targeting proteins. The participation of microRNAs (miRNAs) in experimental investigations has been extensive, and their control functions have earned them the recognition as primary regulators of the human genome. Earlier studies have shown that modulating the expression of miRNAs, either by increasing or decreasing their levels, can initiate the differentiation of osteoblasts. This implies that miRNAs play a pivotal function in promoting osteogenesis, facilitating bone mineralization and formation, ultimately leading to an efficient healing of fractures. Hence, focusing on miRNAs can be considered a propitious therapeutic approach to accelerate the healing of fractures and forestall nonunion. In this manner, the information supplied by this investigation has the potential to aid in upcoming clinical utilization, including its possible use as biomarkers or as resources for devising innovative therapeutic tactics aimed at promoting fracture healing.
Asunto(s)
Fracturas Óseas , MicroARNs , Humanos , Osteogénesis/genética , MicroARNs/genética , MicroARNs/metabolismo , Curación de Fractura/genética , Calidad de Vida , Fracturas Óseas/genética , Fracturas Óseas/terapia , Fracturas Óseas/metabolismo , Osteoblastos/metabolismo , Diferenciación CelularRESUMEN
Introducción y objetivo. El déficit de vitamina D en los ancianos es elevado. Complementar con suplementos de calcio y vitamina D es una práctica habitual en individuos con riesgo de caídas y/o fracturas que, sin embargo, obtiene un bajo grado de cumplimiento. El objetivo es determinar la adherencia al calcio y vitamina D en ancianos con hipovitaminosis D en una zona urbana de Madrid. Pacientes y métodos. Estudio de intervención en 438 individuos ≥ 65 años con hipovitaminosis D procedentes de la «Cohorte Peñagrande». Se les pautó calcio y vitamina D y se valoró la adherencia a los 3 y 12 meses mediante el test de Morisky-Green y el recuento de recetas prescritas. Resultados. Se analizaron 413 de los 438 individuos con hipovitaminosis D (18 casos no se trataron por contraindicaciones y 7 se perdieron). A los 3 y 12 meses el 63,9 y el 47,2%, respectivamente, fueron adherentes. El 19,3% de los no adherentes a los 3 meses fueron buenos cumplidores al año tras una intervención educativa breve. La comorbilidad se asoció con menor adherencia al año (46,3% versus 35,2%, p = 0,027). La principal causa de no adherencia al calcio fue la intolerancia digestiva, y a la vitamina D, los olvidos. Se observó concordancia entre valorar la adherencia con el test de Morisky y recuento de recetas prescritas (índice Kappa = 69,8%). Conclusiones. La falta de adherencia a tratamientos crónicos con calcio y vitamina D es un problema relevante en ancianos. Es importante evaluar la adherencia y aplicar estrategias de educación sanitaria en la práctica clínica (AU)
Background and objective. The vitamin D deficiency is high in the elderly population. Calcium and vitamin D supplements is a frequently used measure in individuals at risk for falls and/or fractures. However, this practice has achieved a low level of compliance. The aim is to assess the adherence to treatment with calcium and vitamin D in elders with hypovitaminosis D in an urban area of Madrid. Patients and methods. Intervention study performed on 438 individuals ≥ 65 years from the Peñagrande Cohort with hypovitaminosis D that were treated with calcium and vitamin D. Adherence at 3 and 12 months was assessed using the Morisky-Green and counting of prescriptions written. Results. A total of 413 of the 438 individuals with hypovitaminosis D were analysed (18 patients were not treated because of contraindications, and 7 were considered lost). At 3 and 12 months, 63.9% and 47.2%, respectively, were adherents. After a brief educational intervention, 19.3% of individuals without adherence at 3 months became good compliers when measured at one year. Comorbidity was associated with lower rates of adherence to treatment after one year (46.3% versus 35.2%, P = .027). The main cause of non-adherence to calcium was digestive intolerance, and due to oversights for vitamin D. Concordance between adherence assessed by the Morisky test and counting of prescriptions written was high (Kappa index = 69.8%). Conclusions. Non-adherence to chronic treatment with calcium and vitamin D is a relevant problem in elderly. It is important to assess adherence and implement health education strategies in clinical practice (AU)
Asunto(s)
Humanos , Masculino , Anciano , Cumplimiento de la Medicación/psicología , Calcio/administración & dosificación , Calcio/farmacología , Atención Primaria de Salud/métodos , España/etnología , Prácticas Clínicas/clasificación , Terapéutica/psicología , Fracturas Óseas/metabolismo , Fracturas Óseas/cirugía , Cumplimiento de la Medicación/etnología , Calcio/clasificación , Calcio/metabolismo , Atención Primaria de Salud/normas , Prácticas Clínicas/métodos , Terapéutica , Fracturas Óseas/psicología , Fracturas Óseas/rehabilitaciónRESUMEN
Las heridas complejas del antebrazo con fracturas asociadas y pérdida circunferencial de piel, suponen un doble reto reconstructivo. Mostramos el tratamiento de una paciente con lesiones combinadas en el miembro superior tras atrapamiento por rodillos fríos industriales mediante el uso de un colgajo libre de perforante del eje epigástrico inferior profundo (DIEP), tras tratamiento de la fractura articular de la extremidad distal de radio guiado por artroscopia. Conseguimos la estabilización de las fracturas y la cobertura completa del defecto. El colgajo DIEP permite la cobertura de áreas extensas con escasa morbilidad en la zona donante y con un correcto resultado estético (AU)
Complex injuries in upper limb like fractures and forearm circumferential skin loss involving are a double reconstructive challenge. We show a case management in a patient with combined injuries in the upper limb because of entrapment by industrial rollers, using deep inferior epigastric perforator free flap (DIEP) after treatment of an articular fracture of distal radius guided by arthroscopy. Was achieved stabilization of fractures and complete coverage of the defect, with good acceptance of the donor site by the patient. DIEP flap provides coverage for large areas with low morbidity and good aesthetic result (AU)
Asunto(s)
Femenino , Humanos , Traumatismos del Antebrazo/rehabilitación , Traumatismos del Antebrazo/cirugía , Colgajos Tisulares Libres/cirugía , Colgajos Tisulares Libres/trasplante , Fracturas Óseas/rehabilitación , Fracturas Óseas/cirugía , Anastomosis Quirúrgica/métodos , Fijación Interna de Fracturas/métodos , Traumatismos del Antebrazo/complicaciones , Traumatismos del Antebrazo/metabolismo , Colgajos Tisulares Libres/normas , Colgajos Tisulares Libres , Fracturas Óseas/complicaciones , Fracturas Óseas/metabolismo , Anastomosis Quirúrgica , Fijación Interna de Fracturas/normasRESUMEN
Reports describing significant health risks due to inadequate vitamin D status continue to generate considerable interest amongst the medical and lay communities alike. Recent research on the various molecular activities of the vitamin D system, including the nuclear vitamin D receptor and other receptors for 1,25-dihydroxyvitamin D and vitamin D metabolism, provides evidence that the vitamin D system carries out biological activities across a wide range of tissues similar to other nuclear receptor hormones. This knowledge provides physiological plausibility of the various health benefits claimed to be provided by vitamin D and supports the proposals for conducting clinical trials. The vitamin D system plays critical roles in the maintenance of plasma calcium and phosphate and bone mineral homeostasis. Recent evidence confirms that plasma calcium homeostasis is the critical factor modulating vitamin D activity. Vitamin D activities in the skeleton include stimulation or inhibition of bone resorption and inhibition or stimulation of bone formation. The three major bone cell types, which are osteoblasts, osteocytes and osteoclasts, can all respond to vitamin D via the classical nuclear vitamin D receptor and metabolize 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D to activate the vitamin D receptor and modulate gene expression. Dietary calcium intake interacts with vitamin D metabolism at both the renal and bone tissue levels to direct either a catabolic action on the bone through the endocrine system when calcium intake is inadequate or an anabolic action through a bone autocrine or paracrine system when calcium intake is sufficient.
Asunto(s)
Humanos , Calcio/metabolismo , Fracturas Óseas/metabolismo , Osteoporosis/metabolismo , Unión Proteica , Receptores de Calcitriol/genética , Vitamina D/análogos & derivadosRESUMEN
INTRODUÇÃO: Foi documentada uma associação entre níveis séricos elevados de homocisteína (S-Hci) e baixa densidade mineral óssea (DMO) e aumento do risco de fratura em mulheres na pós-menopausa. São escassos os dados concernentes à S-Hci e à saúde óssea em crianças. OBJETIVO: Avaliar S-Hci em crianças e adolescentes com comprometimento da saúde óssea e procurar por relações com dados clínicos e laboratoriais. PACIENTES E MÉTODOS: Avaliamos os níveis de S-Hci em 37 crianças e adolescentes (22 meninos e 15 meninas; média de idade, 13,9 ± 3,5 anos) com fraturas prevalentes por trauma de baixa energia (média 3,3 ± 2,3 por paciente) e/ou baixa DMO espinhal/L1-L4 (escore Z abaixo de -2 DP; DXA Lunar GE). Também avaliamos S-ALP, CrossLaps sérico (S-Hci-CrossLaps), osteocalcina (S-OC), altura, peso corporal, índice de massa corporal (IMC) e níveis séricos de folato e vitamina B12. Por ocasião da avaliação, as crianças não estavam tomando qualquer medicação que sabidamente influenciasse o metabolismo ósseo. Os parâmetros dependentes de idade foram expressos como escores Z ± DP. RESULTADOS: O escore Z para S-Hci foi significativamente mais alto (1,3 ± 1,5; P < 0,0001) e o escore Z de para DMO/L1-L4 foi significativamente mais baixo (-1,7 ± 1,3; P < 0,0001), respectivamente, em comparação com os valores de referência. S-ALP não diferiu dos valores de referência (P = 0,88), enquanto S-CrossLaps e S-osteocalcina foram mais elevados (1,2 ± 1,8 e 0,4 ± 0,5; P = 0,0001 e P = 0,001, respectivamente). S-Hci estava inversamente correlacionada com DMO/L1-L4 (r = -0,33; P = 0,05) e S-ALP (r = -0,36; P = 0,04) não tendo relação com o número de fraturas prevalentes (r = 0,01), S-osteocalcina (r = -0,22) ou S-CrossLaps (r = 0,003). CONCLUSÃO: Esses resultados sugerem aumento na remodelação óssea e uma influência negativa da S-Hci elevada na formação óssea e na DMO em crianças e adolescentes com fraturas recorrentes.
INTRODUCTION: Association between high serum homocysteine (S-Hcy) levels and low bone mineral density (BMD) and increased fracture risk in postmenopausal women has been documented. Data concerning S-Hcy and bone health in children are scarce. OBJECTIVE: Our aim was to evaluate S-Hcy in children and adolescents with impaired bone health and look for correlations with clinical and laboratory data. PATIENTS AND METHODS: We assessed S-Hcy levels in 37 children and adolescents (22 boys and 15 girls; mean age 13.9 ± 3.5 years) with prevalent low-energy trauma fractures (mean 3.3 ± 2.3 per patient) and/or low spinal L1-L4 BMD (below -2SD Z-score; DXA Lunar GE). We also evaluated S-ALP, serum CrossLaps, osteocalcin (S-OC), body height, weight, body mass index (BMI) and serum levels of folate and vitamin B12. At the time of assessment, the children were not taking any drugs known to influence bone metabolism. The age-dependent parameters were expressed as Z-scores ± SD. RESULTS: S-Hcy Z-score was significantly higher (1.3 ± 1.5; P < 0.0001) and L1-L4 BMD Z-score was significantly lower (-1.7 ± 1.3; P < 0.0001), respectively, in comparison with reference values. S-ALP did not differ from reference values (P = 0.88), while S-CrossLaps and S-osteocalcin were higher (1.2 ± 1.8 and 0.4 ± 0.5; P = 0.0001 and P = 0.001, respectively). S-Hcy was inversely correlated to L1-L4 BMD (r = -0.33; P = 0.05) and S-ALP (r = -0.36; P = 0.04) and not related to number of prevalent fractures (r = 0.01), S-osteocalcin (r = -0.22) or S-CrossLaps (r = 0.003). CONCLUSION: These results suggest increased bone turnover and negative influence of elevated S-Hcy on bone formation and BMD in children and adolescents with recurrent fractures.
Asunto(s)
Adolescente , Niño , Femenino , Humanos , Masculino , Fracturas Óseas/sangre , Homocisteína/sangre , Densidad Ósea , Huesos/metabolismo , Fracturas Óseas/metabolismoRESUMEN
Osteopontin (OPN) is an acidic, noncollagenous matrix protein produced by the bone and kidneys. It is reportedly involved in bone resorption and formation. We examined the association between serum OPN levels and bone mineral density in postmenopausal women. Premenopausal women (n=32) and postmenopausal women (n=409) participated in the study. We measured serum osteopontin levels and their relationships with bone mineral density and previous total fragility fractures. The postmenopausal women had higher mean serum OPN levels compared to the premenopausal women (43.6+/-25.9 vs 26.3+/-18.6 ng/mL; P<0.001). In the postmenopausal women, high serum OPN levels were negatively correlated with mean lumbar bone mineral density (BMD) (r=-0.113, P=0.023). In a stepwise multiple linear regression model, serum OPN levels were associated with BMD of the spine, femoral neck, and total hip after adjustment for age, body mass index, smoking, and physical activity in postmenopausal women. However, serum OPN levels did not differ between postmenopausal women with and without fractures. Postmenopausal women exhibit higher serum OPN levels than premenopausal women and higher serum OPN levels were associated with low BMD in postmenopausal women.
Asunto(s)
Anciano , Femenino , Humanos , Persona de Mediana Edad , Densidad Ósea/fisiología , Cuello Femoral/metabolismo , Fracturas Óseas/metabolismo , Modelos Lineales , Osteopontina/sangre , Posmenopausia , Premenopausia , Columna Vertebral/metabolismoRESUMEN
OBJETIVO: Revisar os mecanismos de ações dos glicocorticoides e sua capacidade de induzir osteoporose e déficits de crescimento. FONTES DOS DADOS: A revisão bibliográfica de artigos científicos foi realizada na base de dados MEDLINE e utilizou as palavras-chave agrupadas nas sintaxes glicocorticoides, mineralização óssea, crescimento e efeitos colaterais, nos últimos 10 anos, e das referências destes nos reportamos para as publicações mais antigas, mas com os estudos fundamentais para a compreensão do assunto. SÍNTESE DOS DADOS: Destacam-se ações dos glicocorticoides sobre hormônios e citocinas responsáveis pelo crescimento longitudinal. Os efeitos finais dos glicocorticoides sobre o esqueleto são determinados por ações sistêmicas no metabolismo ósseo e por ações diretas desses esteroides nas células ósseas, levando a mudanças no número e função das mesmas e favorecendo a perda óssea. Discutem-se os mecanismos indutores da recuperação dos canais de crescimento e recuperação da massa óssea após a descontinuação dos glicocorticoides; os métodos diagnósticos do metabolismo e mineralização óssea; assim como medidas terapêuticas e preventivas das alterações óssea induzidas pelos glicocorticoides. CONCLUSÃO: A monitorização de cada paciente é essencial para identificação e potencial reversão dos danos associados ao uso crônico de glicocorticoides.
OBJECTIVE: To review the various mechanisms of glucocorticoid action and the ability of these agents to induce osteoporosis and growth deficits. SOURCES: A review of the scientific literature was conducted on the basis of a MEDLINE search using the keywords and descriptors glucocorticoids, bone mineralization, growth, and side effects and limited to articles published in the last decade. The references cited by these articles were used to identify relevant older publications, with an emphasis on landmark studies essential to an understanding of the topic. SUMMARY OF THE FINDINGS: Emphasis was placed on the actions of glucocorticoids on the hormones and cytokines that modulate linear growth. The end effects of glucocorticoids on the skeletal system are the result of systemic effects on bone metabolism and of direct actions on bone cells, which alter bone cell counts and predispose to bone loss. The mechanisms underlying catch-up growth and bone mass recovery after discontinuation of glucocorticoid treatment are discussed, followed by a review of diagnostic methods available for assessment of bone metabolism and mineralization and of measures for prevention and management of glucocorticoid-induced bone changes. CONCLUSION: Patient monitoring on a case-by-case basis plays an essential role in detection and, potentially, reversal of the damage associated with chronic glucocorticoid therapy.
Asunto(s)
Adolescente , Adulto , Femenino , Humanos , Masculino , Densidad Ósea/efectos de los fármacos , Desarrollo Óseo/efectos de los fármacos , Glucocorticoides/efectos adversos , Osteoporosis/inducido químicamente , Fracturas Óseas/inducido químicamente , Fracturas Óseas/metabolismo , Osteoporosis/metabolismo , Factores de RiesgoRESUMEN
En las últimas décadas, nuestro grupo de trabajo ha contribuido a desarrollar algunas de las nuevas ideas sobre las verdaderas características estructurales que definen la llamada ôcalidad óseaõ, y sus relaciones con sus determinantes genéticos y con la influencia de los entornos mecánico y sistémico que afectan a las células óseas.La moderna corriente es suficientementeimportante como para haber desviadoel interés de los sponsors internacionales de estudios clínicos controlados. El antiguo estudio densitométrico de masas mineralizadas, y el análisis bioquímico de indicadores del turnover óseo, ceden prioridad hoy al estudio de imágenes seccionales osteo-musculares con criterio biomecánico, y al análisis de las interacciones músculo-hueso. Este conocimiento configura ya una unidadconceptual suficientemente coherentecomo para ser divulgado en forma integrada, para uso del médico práctico. Pese a la obvia complejidad del marco teórico del tema en cuestión, los aspectos más relevantes de la nueva corriente de pensamiento para la correcta interpretación de la Osteología moderna pueden resumirse en 13 puntos críticos, cada uno de ellos defácil comprensión si se lo analiza por separado. A continuación se expone una secuencia didáctica de esos 13 puntos, que enumera y describe, para cada uno de ellos, una triada de aspectos fundamentales para su comprensióny asimilación a la nueva corriente, y deriva de ellos un mensaje práctico para su aplicación fisiopatológica, clínica, o terapéutica.
Asunto(s)
Humanos , Masculino , Femenino , Fenómenos Biomecánicos , Desarrollo Óseo/genética , Fracturas Óseas/genética , Fracturas Óseas/metabolismo , Estructuras Genéticas , Huesos/fisiología , Huesos/metabolismoRESUMEN
La osteoporosis es la enfermedad ósea más frecuente cuya complicación clínica son las fracturas, siendo la vertebral la más prevalerte. Disponemos hoy en día de un número de fármacos que reducen la aparición de nuevas fracturas y entre estos ocupan un papel fundamental los bifosfonatos. Sin embargo para que se produzca la reducción de fracturas, el tratamiento debe realizarse correctamente a largo plazo, y una gran proporción de pacientes abandonan la medicación al cabo de pocos meses por distintas razones. La introducción en el arsenal terapéutico contra la osteoporosis de bifosfonatos que permiten la administración más separada en el tiempo, semanal e incluso mensualmente, ha mejorado notablemente la adherencia al tratamiento
Osteoporosis is the most prevalent metabolic bone disease and fractures are its clinical complication. We have nowadays some drugs that reduce the incidence of new fractures: Bisphosphonates. Nevertheless, treatment must be taken properly in the long run to reduce the incidente of new fractures and a few months alter starting the treatment, a great number of patients stop it because of different reasons. The introduction of new bisphosphonates that can be taken weekly or even better monthly, has improved notably the adherence and compliance to osteoporosis treatment
Asunto(s)
Masculino , Femenino , Humanos , Difosfonatos/administración & dosificación , Osteoporosis/complicaciones , Osteoporosis/tratamiento farmacológico , Calidad de Vida , Absorción Intestinal , Alendronato/uso terapéutico , Fracturas Óseas/tratamiento farmacológico , Densidad Ósea , Densidad Ósea/fisiología , Fracturas Óseas/epidemiología , Fracturas Óseas/metabolismo , Fracturas Óseas/complicaciones , Fracturas Óseas/diagnósticoRESUMEN
With the ageing population in most countries, disorders of bone and mineral metabolism are becoming increasingly relevant to every day clinical practice. Consequently, the interest in, and the need for effective measures to be used in the screening, diagnosis and follow-up of such pathologies have markedly grown. Together with clinical and imaging techniques, biochemical tests play an important role in the assessment and differential diagnosis of metabolic bone disease. In recent years, the isolation and characterisation of cellular and extracellular components of the skeletal matrix have resulted in the development of molecular markers that are considered to reflect either bone formation or bone resorption. These biochemical indices are non-invasive, comparatively inexpensive and, when applied and interpreted correctly, helpful tools in the diagnostic and therapeutic assessment of metabolic bone disease. This review provides an overview of the current evidence regarding the clinical use of biochemical markers of bone remodelling in bone disease, with an emphasis on osteoporosis.
Tendo em vista o crescimento da população idosa na maioria dos países, os distúrbios do metabolismo ósseo e mineral estão tornando-se cada vez mais relevantes na prática clínica diária. Conseqüentemente, o interesse e a necessidade de medidas efetivas para serem usadas no rastreamento, diagnóstico e seguimento de tais patologias vêm crescendo acentuadamente. Além da avaliação clínica e de técnicas de imagens, os marcadores bioquímicos desempenham um importante papel na avaliação e diagnóstico das doenças ósseas metabólicas. Recentemente, a melhor caracterização dos componentes intracelulares e extracelulares da matriz óssea resultou no desenvolvimento dos marcadores moleculares, os quais refletem tanto a formação como a reabsorção óssea. Estes marcadores bioquímicos não são invasivos e comparativamente são de mais baixo custo, e quando aplicados e interpretados corretamente são instrumentos úteis no diagnóstico e tratamento das doenças ósseas metabólicas. Esta revisão abordará evidências atuais, levando em consideração o uso clínico dos marcadores bioquímicos da remodelação óssea nas doenças metabólicas ósseas, com ênfase na osteoporose.